These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 22511592

  • 1. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.
    Rozenman Y, Mehran R, Witzenbichler B, Dangas G, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, Stone GW.
    Catheter Cardiovasc Interv; 2013 Jan 01; 81(1):E9-14. PubMed ID: 22511592
    [Abstract] [Full Text] [Related]

  • 2. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, GRACE Investigators.
    Am Heart J; 2007 Jun 01; 153(6):960-9. PubMed ID: 17540196
    [Abstract] [Full Text] [Related]

  • 3. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, HORIZONS-AMI Trial Investigators.
    Lancet; 2009 Oct 03; 374(9696):1149-59. PubMed ID: 19717185
    [Abstract] [Full Text] [Related]

  • 4. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R.
    JACC Cardiovasc Interv; 2011 Sep 03; 4(9):1011-9. PubMed ID: 21939942
    [Abstract] [Full Text] [Related]

  • 5. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS, Ottervanger JP, ten Berg JM, Gosselink AT, van Houwelingen G, Dambrink JH, Stella PR, Hamm C, van 't Hof AW, On-TIME 2 Trial Investigators.
    J Invasive Cardiol; 2012 Mar 03; 24(3):84-9. PubMed ID: 22388296
    [Abstract] [Full Text] [Related]

  • 6. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial).
    Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW.
    Am J Cardiol; 2010 May 15; 105(10):1385-94. PubMed ID: 20451683
    [Abstract] [Full Text] [Related]

  • 7. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH, Shah P, Kinnaird T, Pinto Slottow TL, Roy PK, Okabe T, Bonello L, de Labriolle A, Smith KA, Torguson R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R.
    Am J Cardiol; 2008 Jul 15; 102(2):160-4. PubMed ID: 18602514
    [Abstract] [Full Text] [Related]

  • 8. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D, Collet JP, Silvain J, Landivier A, Barthélémy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G.
    Catheter Cardiovasc Interv; 2011 Feb 01; 77(2):182-90. PubMed ID: 20578166
    [Abstract] [Full Text] [Related]

  • 9. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW, Clayton T, Deliargyris EN, Prats J, Mehran R, Pocock SJ.
    J Am Coll Cardiol; 2011 Feb 01; 63(1):15-20. PubMed ID: 24140664
    [Abstract] [Full Text] [Related]

  • 10. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy: A retrospective cohort study.
    Mallidi JR, Robinson P, Visintainer PF, Lotfi AS, Mulvey S, Giugliano GR.
    Catheter Cardiovasc Interv; 2017 Nov 15; 90(6):898-904. PubMed ID: 28417608
    [Abstract] [Full Text] [Related]

  • 11. Defining optimal activated clotting time for percutaneous coronary intervention: A systematic review and Bayesian meta-regression.
    Mottillo S, Filion KB, Joseph L, Eisenberg MJ.
    Catheter Cardiovasc Interv; 2017 Feb 15; 89(3):351-366. PubMed ID: 27545117
    [Abstract] [Full Text] [Related]

  • 12. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
    Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L, EVENT Registry Investigators, Boston, MA.
    Circ Cardiovasc Interv; 2011 Oct 01; 4(5):463-73. PubMed ID: 21972401
    [Abstract] [Full Text] [Related]

  • 13. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E, ExTRACT-TIMI 25 Investigators.
    J Am Coll Cardiol; 2007 Jun 12; 49(23):2238-46. PubMed ID: 17560287
    [Abstract] [Full Text] [Related]

  • 14. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.
    J Am Coll Cardiol; 2010 Jun 08; 55(23):2556-66. PubMed ID: 20513595
    [Abstract] [Full Text] [Related]

  • 15. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E.
    J Invasive Cardiol; 2006 Nov 08; 18(11):521-6. PubMed ID: 17090813
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ, Califf RM.
    Am Heart J; 2006 Dec 08; 152(6):1042-50. PubMed ID: 17161049
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction.
    Iqbal Z, Cohen M, Pollack C, Goldstein P, Zeymer U, Huber K, Barthelemy O, Cayla G, Aout M, Vicaut E, Montalescot G, ATOLL Investigators.
    Am J Cardiol; 2013 Jun 15; 111(12):1727-33. PubMed ID: 23528027
    [Abstract] [Full Text] [Related]

  • 18. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P, Cohen EA, Batchelor W, Lazzam C, Kreatsoulas C, Natarajan MK, Strauss BH.
    Am Heart J; 2001 Feb 15; 141(2):218-25. PubMed ID: 11174335
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
    Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Na Y, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Rutherford BD, Lansky AJ, Mehran R.
    Am J Cardiol; 2007 Jan 15; 99(2):202-7. PubMed ID: 17223419
    [Abstract] [Full Text] [Related]

  • 20. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
    Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D.
    EuroIntervention; 2013 May 20; 9(1):118-24. PubMed ID: 23410540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.